Alexion Pharmaceuticals Inc. is anticipated to pay greater than $21 million to settle costs of violations of the International Corrupt Practices Act, in keeping with the Securities and Trade Fee.
Two of Alexion’s subsidiaries—Alexion Turkey and Alexion Russia—bribed overseas authorities officers to favorably deal with an organization product Soliris, the SEC mentioned on Thursday. For the Turkey subsidiary, this lasted from 2010 to 2015. For the Russia subsidiary, it was from 2011 to 2015.
The regulator additionally mentioned that each subsidiaries “maintained false books and information of those improper funds” and that the corporate’s “inner accounting controls weren’t adequate to detect or forestall” these.
The SEC additionally mentioned Alexion Colombia and Brazil subsidiaries “failed to keep up correct books and information.”